On June 25, 2000, President Clinton announced the completion of the first survey of the entire human genome. This single event created a quantum growth opportunity to provide advanced informatics solutions to R&D drug discovery & development in the Pharmaceuticals industry. TechCo, a Fortune 50 company saw the potential but had numerous challenges. A new Business Unit was formed and Vaxa was engaged to assist them with the creation of their strategic & tactical options. Some of the questions Vaxa was faced with were: What are the business and computation-related plays within drug discovery & development R&D? What are the most attractive opportunities? What capabilities & assets are necessary for success? What are market entry strategic & tactical options & details? What are our revenue targets and how do we attain them?
		To provide fact-based guidance to the strategy and tactics, Vaxa conducted a wide and deep body of global research. This research engaged all segments of market. Vaxa closely collaborated with the client's global teams in the Americas, Europe, & Asia-Pacific to apply our market foresight and insights to determine which opportunities are most attractive and developing detailed implementation tactics. top
		The client built a global business to serve all major customer segments - e.g., Pharmaceuticals, Biotechnology, Government, & Academia. This included major investments in emerging companies, designing wholly new technology solutions for drug discovery & development, creating a global partner and alliance ecosystem, and capturing about a 5% marketshare in less than three (3) years. According to Fortune Magazine, the Business Unit added annual revenues of over $1B to its Corporation's top line. top